Free shipping on all orders over $ 500

ML141 (CID-2950007)

Cat. No. M6968
ML141 (CID-2950007) Structure
Synonym:

CID-2950007

Size Price Availability Quantity
5mg USD 85  USD85 In stock
10mg USD 140  USD140 In stock
50mg USD 475  USD475 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ML141 (CID-2950007) is a allosteric inhibitor of Cdc42 GTPase (EC50 = 2.1 μM). Selective for Cdc42 over other members of the Rho GTPase family including Rac1, Rab2 and Rab7. Inhibits ovarian cancer cell migration in vitro.

Chemical Information
Molecular Weight 407.49
Formula C22H21N3O3S
CAS Number 71203-35-5
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Howlett, et al. Neuropharmacology. Stereochemical effects of 11-OH-Δ8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor.

Related Ras Products
BBO-8520

BBO-8520 is a first-in-class orally active covalent KRAS G12C inhibitor. BBO-8520 inhibits KRASG12C (ON) by locking the GTP-binding protein in state 1, a conformation incapable of binding effectors, thereby inhibiting the downstream signaling of KRASG12C (ON) that promotes cell proliferation. BBO-8520 also rapidly and completely blocks the RAS-RAF1 interaction, returning KRASG12C to its inactive (OFF) state.

RMC-9805

RMC-9805 (KRAS G12D inhibitor 18) is an orally active KRAS G12D inhibitor. RMC-9805 (KRAS G12D inhibitor 18) inhibits RAS signaling and induces apoptosis in KRAS G12D mutant cancer cells.

RMC-7977

RMC-7977 is a highly selective, reversible, tri-complex RAS inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants. RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X).

KRpep-2d

KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells.

Rac1 Inhibitor W56

Rac1 Inhibitor W56 is a peptide containing residues 45-60 of Rac1.

  Catalog
Abmole Inhibitor Catalog




Keywords: ML141 (CID-2950007), CID-2950007 supplier, Ras, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.